News & Updates

The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.

A cross-sectional study from the Chinese University of Hong Kong suggests that Parkinson’s disease (PD)–like gut dysbiosis occurs at preclinical prodromal stages of PD, in patients with video-polysomnography (v-PSG)–confirmed REM sleep behavior disorder (RBD) and even in their younger first-degree relatives (RBD-FDR).

Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.

Perampanel appears to be effective and have good tolerability in patients with idiopathic generalized epilepsy treated in everyday clinical practice settings, as shown in a study.

A study in India has shown the effectiveness of a small cash transfer in alleviating short-term functional impairment among older people who are living alone. However, cash transfers do not produce a clinically or statistically significant decrease in depression and show no impact on food security.

People who regularly consume sugar-sweetened (SSBs) and artificially sweetened beverages (ASBs) appear to be at greater risk of dementia, but those who drink natural juices (NJs) in moderation show a reduced risk, suggests a study.